XARELTO® (rivaroxaban) is safe to use in elderly patients with nonvalvular atrial fibrillation, an analysis published in Circulation finds.

The ROCKET AF trial looked at patients over age 75, and found the use of rivaroxaban, a daily oral anticoagulant, is a viable alternative to warfarin. XARELTO® does not require routine blood monitoring and has no known food restrictions and limited drug interactions.

Consistent safety and efficacy results with XARELTO® were achieved across NVAF patient subgroups at high risk of stroke, such as those with prior stroke or co-occurring medical conditions, including moderate renal impairment, chronic heart failure and diabetes.

Eight million patients have received the medication, which is believed to have broad applications. It can be used to reduce the risk of strokes and blood clots in patients with atrial fibrillation not caused by a heart valve problem, to treat deep vein thrombosis, to treat pulmonary embolism, to reduce the recurrence of DVT or PE following treatment for acute venous thromboembolism, and to reduce the risk of clots in the legs and lungs of people who have had knee or hip replacement surgery.